Table 2 Pathological outcomes of the ALK-positive and ALK-negative groups
Variables | ALK+ (n = 65) | ALK- (n = 629) | Χ2(t) | P-value |
|---|---|---|---|---|
Pathological type | Â | Â | 3.240 | 0.101 |
 SCC | 0 (0) | 30 (4.8) |  |  |
 ADC | 65 (100) | 599 (95.2) |  |  |
Cell differentiation | ||||
 Well | 16 (24.6) | 123 (19.5) | 0.942 | 0.332 |
 Moderate | 30 (46.2) | 376 (59.8) | 4.504 | 0.034a |
 Poor | 19 (29.2) | 130 (20.7) | 2.562 | 0.109 |
Mucinous | 9 (13.8) | 34 (5.4) | 7.222 | 0.007a |
≥5% Micropapillary/solid subtype | 16 (24.6) | 124 (19.7) | 0.879 | 0.348 |
 VPI | 24 (36.9) | 300 (47.7) | 2.746 | 0.097 |
Lymphovascular invasion | 0 (0) | 11 (1.7%) | 1.155 | 0.282 |
 STAS | 3 (4.6) | 10 (1.6) | 2.934 | 0.114 |
 Ki-67 (IQR) | 5 (5, 10) | 7 (3, 15) | 0.277 | 0.782 |
 PD-1 (IQR) | 8 (1, 10) | 5 (2, 10) | 0.844 | 0.399 |
 PD-L1 (IQR) | 0 (0, 2) | 0 (0, 2) | 0.020 | 0.984 |
 EGFR | 9/65 (13.8) | 242/347 (69.7) | 71.842 | < 0.001a |
 KRAS | 1/65 (1.5) | 29/336 (8.6) | 3.000 | 0.083 |
 TP53 | 2/20 (10.0) | 51/239 (21.3) | 1.458 | 0.385 |
pTNM stage |  |  | – | 1 |
 IA/IB | 34 (52.3)/30 (46.2) | 275 (43.7)/343 (54.5) |  |  |
 IIA/IIB | 0 (0)/1 (1.5) | 11 (1.8)/0 (0) |  |  |